PAR 3.92% 24.5¢ paradigm biopharmaceuticals limited..

Ann: iPPS Increases Cartilage Thickness in Phase 2 Trial, page-60

  1. 2,135 Posts.
    lightbulb Created with Sketch. 573
    They aren't under clinical hold with the FDA - I don't think this is an issue.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.